The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for August 2019 (PDF).
This month clinicians are advised that naltrexone/bupropion (Mysimba®) has been linked with adverse reactions that could affect ability to drive. This medicine is licensed for the management of weight in obese adults and in overweight adults with one or more weight-related conditions. Usage levels in the UK are low and it is mainly issued on private prescription. Use has been linked with dizziness or somnolence, which can affect ability to drive, operate machinery, or perform dangerous tasks. Advise patients not to drive if they suspect their ability may be impaired.
The summary of letters to healthcare professionals this month includes details of two patient-level medicine recalls for Neupro 4mg/24hr patches and Vimpat 100mg tablets. Any patient that has any of these affected products is advised to continue taking their medicines and contacting their prescriber to arrange a new prescription. Patients should return the affected batches to their pharmacist once they have a new prescription.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.